Cargando…

Large-scale use of hydroxychloroquine for COVID-19 confirms safety, if not effectiveness

Detalles Bibliográficos
Autores principales:	Cavalli, Giulio, Dagna, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Federation of Internal Medicine. Published by Elsevier B.V. 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598356/ https://www.ncbi.nlm.nih.gov/pubmed/33132004 http://dx.doi.org/10.1016/j.ejim.2020.10.023

Ejemplares similares

Effect of anakinra in COVID-19 – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2020)

The course of action for effective anti-cytokine treatment in COVID-19
por: Cavalli, Giulio, et al.
Publicado: (2021)

The right place for IL-1 inhibition in COVID-19
por: Cavalli, Giulio, et al.
Publicado: (2021)

Hydroxychloroquine in COVID-19: The Study Points to Premature Decisions on Efficacy While Bells Ringing for Safety
por: Khadka, Sitaram, et al.
Publicado: (2020)

Does hydroxychloroquine reduce mortality for COVID-19?
por: GALLUS, Silvano, et al.
Publicado: (2020)

Hydroxychloroquine for COVID-19: Balancing contrasting claims
por: Horby, Peter W., et al.
Publicado: (2020)

Updates on Hydroxychloroquine in Prevention and Treatment of COVID-19
por: Hennekens, Charles H., et al.
Publicado: (2022)

Interleukin 6 inhibition in severe COVID-19: Another piece of the puzzle
por: Farina, Nicola, et al.
Publicado: (2022)

Risk of using hydroxychloroquine as a treatment of COVID-19
por: Alanagreh, Lo’ai, et al.
Publicado: (2020)

Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: A pilot observational study
por: Sogut, Ozgur, et al.
Publicado: (2021)

Within a large healthcare system, the incidence of positive COVID-19 results and mortality are lower in patients on chronic hydroxychloroquine therapy
por: Sen, Soma, et al.
Publicado: (2020)

Anakinra for patients with COVID-19 – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2020)

Hydroxychloroquine and COVID-19: can we learn from the use of rituximab in systemic lupus erythematosus?
por: Lekpa, Fernando Kemta, et al.
Publicado: (2021)

Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome
por: Okour, Malek, et al.
Publicado: (2020)

Enhancing the indicator for COVID-19 confirmed cases
por: Ferdosi, Masoud, et al.
Publicado: (2020)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2021)

Hydroxychloroquine and COVID-19: a Rheumatologist’s Take on the Lessons Learned
por: Udupa, Akrithi, et al.
Publicado: (2021)

Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy
por: Scherrmann, JM.
Publicado: (2020)

Lessons from a large-scale COVID-19 vaccine trial
por: Mahla, Ranjeet Singh, et al.
Publicado: (2022)

Mavrilimumab for severe COVID-19 – Authors' reply
por: De Luca, Giacomo, et al.
Publicado: (2020)

Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak
por: Nicolò, Massimo, et al.
Publicado: (2020)

Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients
por: Eftekhar, Seyed Parsa, et al.
Publicado: (2021)

Reply to Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin
por: Million, Matthieu, et al.
Publicado: (2021)

Can Cytokine Blocking Prevent Depression in COVID-19 Survivors?
por: Benedetti, Francesco, et al.
Publicado: (2020)

Recent Findings on Cardiovascular Safety With the Use of Chloroquine and Hydroxychloroquine for COVID-19
por: Guzman-Prado, Yuli
Publicado: (2020)

Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19
por: Gevers, S., et al.
Publicado: (2020)

Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis
por: Faruqui, Atiya R., et al.
Publicado: (2021)

PRAC review confirms chloroquine- and hydroxychloroquine-related AEs
Publicado: (2020)

Cutaneous vasculitis following COVID-19 vaccination
por: Cavalli, Giulio, et al.
Publicado: (2021)

Has the door closed on hydroxychloroquine for SARS-COV-2?
por: Paul, Mical
Publicado: (2021)

Confirming validity of The Fear of COVID-19 Scale in Japanese with a nationwide large-scale sample
por: Midorikawa, Haruhiko, et al.
Publicado: (2021)

Correction to: Can Cytokine Blocking Prevent Depression in COVID-19 Survivors?
por: Benedetti, Francesco, et al.
Publicado: (2021)

Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro
por: Clementi, Nicola, et al.
Publicado: (2020)

Hydroxychloroquine: A review of its safety and efficacy in COVID-19
por: Karia, Rutu H., et al.
Publicado: (2021)

Cardiovascular Safety of Hydroxychloroquine–Azithromycin in 424 COVID-19 Patients
por: Million, Matthieu, et al.
Publicado: (2023)

Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2
por: Ingraham, Nicholas E., et al.
Publicado: (2020)

From hydroxychloroquine to ivermectin: how unproven “cures” can go viral
por: Taccone, Fabio Silvio, et al.
Publicado: (2022)

Safety Consequences of Off-Label Drugs Used for COVID-19
por: Dasgupta, Nabarun
Publicado: (2021)

Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial
por: Sivapalan, Pradeesh, et al.
Publicado: (2022)

Large-scale dynamics of horizontal transfers
por: Grassi, Luigi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_a1osa4nts1llarm7pu41be2aps